Results 81 to 90 of about 21,299 (206)

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole

Pharmacogenomics and Personalized Medicine, 2018
Natalia P Denisenko,1–3 Dmitriy A Sychev,2 Zhanna M Sizova,3 Valeriy V Smirnov,4,5 Kristina A Ryzhikova,1 Zhannet A Sozaeva,1 Elena A Grishina1 1Research Center, Russian Medical Academy of Continuous Professional Education, Ministry of Healthcare ...
Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, Sozaeva ZA, Grishina EA   +6 more
doaj  

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole

Clinical and Translational Science
Voriconazole is the cornerstone of the treatment and prevention of fungal infections. While there is a good correlation between CYP2C19 genotype and voriconazole exposure during prophylactic treatment, no correlation was found in patients with invasive ...
Sylvia D. Klomp, Anette Veringa, Jan‐Willem C. Alffenaar, Mark G. J. deBoer, Lambert F. R. Span, Henk‐Jan Guchelaar, Jesse J. Swen   +6 more
doaj   +1 more source

Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method

Drug Design, Development and Therapy, 2023
Xin Liu,1– 3 Gehang Ju,1– 3 Wenyu Yang,4 Lulu Chen,3,5,6 Nuo Xu,4 Qingfeng He,4 Xiao Zhu,4,* Dongsheng Ouyang1– 3,5,* 1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People’s Republic of China ...
Liu X, Ju G, Yang W, Chen L, Xu N, He Q, Zhu X, Ouyang D   +7 more
doaj  

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE

Рациональная фармакотерапия в кардиологии, 2017
Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization of antiplatelet therapy in patients with acute coronary syndrome (ACS) in routine practice.Material and methods.
A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina   +4 more
doaj   +1 more source

Benchmark of Open‐Access Star‐Allele Callers to Accurately Assess Haplotypes and Phenotypes in Pharmacogenetic Studies

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 520-530, August 2026.
Genetic polymorphisms are common in pharmacogenes, with sometimes important implications for drug metabolism. Assessing the correct enzyme phenotype from genetic data is thus a crucial step into the development of personalized medicine. Many bioinformatics star‐allele callers have been developed for this purpose of identifying the correct star alleles ...
Marc B. Gros‐La‐Faige, Emmanuelle Génin, Anthony F. Herzig   +2 more
wiley   +1 more source

Association between CYP2C19 gene polymorphisms and Helicobacter pylori infection in Hainan region

BMC Infectious Diseases
Objective This study was to investigate CYP2C19 gene and their association with H. pylori infection in the region of Hainan. Methods We conducted CYP2C19 genotype analysis in Hainan.
Shimei Huang, Daya Zhang, Da Li, Chen Chen, Fan Zeng, Shiju Chen, Runxiang Chen, Xiaodong Zhang, Feihu Bai   +8 more
doaj   +1 more source

Exploring the Potential Role of CYP2C19 Genetic Variability in Cenobamate Treatment

Applied Sciences
Background: Cenobamate is a novel antiseizure medication with potential interactions involving cytochrome P450 enzymes, including CYP2C19. Genetic variability in CYP2C19 may influence drug metabolism and tolerability, although its clinical relevance in ...
Giovanni Falcicchio, Valeria Delmonte, Teresa Francavilla, Alessandro Introna, Maria Addolorata Mariggiò, Mariella Pafundi, Mirko Perrone, Angela Vinella, Emilio Russo   +8 more
doaj   +1 more source

Design, Synthesis, and Biological Evaluation of Chiral Urea and Thiourea Derivatives as Multitarget‐Directed Anti‐Alzheimer Agents

Drug Development Research, Volume 87, Issue 5, August 2026.
ABSTRACT A series of novel chiral urea and thiourea compounds were designed as multitarget‐directed ligands for Alzheimer's disease and evaluated against hAChE, hBChE, and hMAO‐B, with exploratory assessment of HSD10. These chiral compounds were synthesized and fully characterized, and their enantiopurity was confirmed via HPLC.
Sule Erol Gunal, Senel Teke Tuncel, İlke Demir, İpek Baysal, Gökçen Telli, Safiye Sag Erdem, Gulberk Ucar, Michaela Hanzlova, Kamil Musilek, İlknur Dogan, Nesrin Gokhan Kelekci   +10 more
wiley   +1 more source

Phase I Metabolism of Novel Phencyclidine Derivative 3‐Cl‐PCP: In Vitro Studies With Pooled Human Liver Microsomes and Investigation of a Post‐Mortem Case

Drug Testing and Analysis, Volume 18, Issue 8, Page 1036-1053, August 2026.
A fatal 3‐chloro‐phencyclidine (3‐Cl‐PCP) intoxication was investigated by analyzing postmortem samples and a pooled human liver microsomes assay. Tentative metabolite identification was performed by liquid chromatography‐quadrupole time‐of‐flight mass spectrometry (LC‐QTOF‐MS). Seven phase I metabolites were identified.
Johannes Kutzler, Tobias Veit, Thomas Keller, Volker Auwärter   +3 more
wiley   +1 more source